Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
暂无分享,去创建一个
J. Moore | D. Ho | J. Binley | Y. Cao | M. Markowitz | P. Klasse | I. Jones | Yun-zhen Cao | P J Klasse | D D Ho | Y Cao | M Markowitz | J P Moore | J M Binley | I Jones | Y. Cao | Y. Cao | David D. Ho | John P. Moore | Ian M. Jones
[1] David Gray,et al. Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.
[2] Reed J. Harris,et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.
[3] T. Spira,et al. Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody , 1996, Journal of virology.
[4] S. Porcelli,et al. Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells. , 1994, Nature.
[5] P. Brennan,et al. CD1-restricted T cell recognition of microbial lipoglycan antigens. , 1995, Science.
[6] D. Montefiori,et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. , 1996, The Journal of infectious diseases.
[7] H. Katinger,et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate , 1996, Journal of virology.
[8] D. Cooper,et al. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion. , 1994, The Journal of infectious diseases.
[9] L. Chieco‐Bianchi,et al. Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects. , 1988, Clinical immunology and immunopathology.
[10] L. Bélec,et al. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. , 1995, The Journal of infectious diseases.
[11] A. Alberti,et al. HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. , 1989, Journal of immunology.
[12] A. Lanzavecchia,et al. T cells can present antigens such as HIV gp120 targeted to their own surface molecules , 1988, Nature.
[13] A. Lanzavecchia,et al. Specific B lymphocytes efficiently pick up, process and present antigen to T cells. , 1985, Behring Institute Mitteilungen.
[14] J. Weber,et al. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. , 1991, BMJ.
[15] A. Fauci,et al. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. , 1993, Science.
[16] G R Pilkington,et al. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. , 1993, Journal of molecular biology.
[17] R. Kurth,et al. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. , 1996, Virology.
[18] M. Björklund,et al. 'Background' immunoglobulin production: measurement, biological significance and regulation. , 1982, Immunology today.
[19] W. Rozenbaum,et al. Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as prognostic marker. , 1992, The Journal of infectious diseases.
[20] A. Heredia,et al. HIV‐1 Causing AIDS and Death in a Seronegative Individual , 1994, Vox sanguinis.
[21] S. Zolla-Pazner,et al. B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. , 1988, Clinical and experimental immunology.
[22] R. Garry,et al. A general model for the surface glycoproteins of HIV and other retroviruses. , 1995, AIDS research and human retroviruses.
[23] Y. Masuho,et al. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. , 1991, Virology.
[24] Barney S. Graham,et al. Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1 , 1994 .
[25] D. Ho,et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.
[26] I. Jones,et al. Functions of HIV envelope glycans. , 1994, Trends in biochemical sciences.
[27] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[28] M. Ascher,et al. The initial immune response to HIV and immune system activation determine the outcome of HIV disease. , 1991, Journal of acquired immune deficiency syndromes.
[29] S. Porcelli,et al. CDlb restricts the response of human CD4−8−T lymphocytes to a microbial antigen , 1992, Nature.
[30] J. McCutchan,et al. Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals. , 1994, AIDS research and human retroviruses.
[31] M. Wainberg,et al. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. , 1990, The Journal of infectious diseases.
[32] B. Korber,et al. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes , 1996, Journal of virology.
[33] A. Heredia,et al. Sequence analysis of the V1/V2 and V3 domains in an HIV-seronegative AIDS patient. , 1995, AIDS research and human retroviruses.
[34] J. Sodroski,et al. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.
[35] C. Kuiken,et al. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. , 1994, Virology.
[36] B. Graham,et al. Candidate AIDS vaccines. , 1995, The New England journal of medicine.
[37] R. Steinman,et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing , 1995, Nature.
[38] F. de Wolf,et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. , 1995, The Journal of infectious diseases.
[39] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[40] J. Moore,et al. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization , 1991, Journal of virology.
[41] J. Hansen,et al. Autologous HIV‐1 Neutralizing Antibodies: Emergence of Neutralization‐Resistant Escape Virus and Subsequent Development of Escape Virus Neutralizing Antibodies , 1992, Journal of acquired immune deficiency syndromes.
[42] R. Kurth,et al. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides. , 1994, Journal of immunology.
[43] Donald E. Broadbent,et al. Memories are made of this , 1977, Nature.
[44] D. Ho,et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.
[45] S. Oka,et al. Genetic analysis of HIV-1 during rapid progression to AIDS in an apparently healthy man. , 1994, AIDS research and human retroviruses.
[46] P. Klasse. Physico-chemical Analyses of the Humoral Immune Response to HIV-1 : Quantification of Antibodies , Their Binding to Viral Antigens and Neutralization of Viral Infectivity , 1997 .
[47] R. Lamb,et al. Folding and assembly of viral membrane proteins. , 1993, Virology.
[48] J. Moore,et al. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. , 1995, AIDS.
[49] J. Moore,et al. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 , 1994, Journal of virology.
[50] Ashley T. Haase,et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.
[51] R. Ahmed,et al. Bone marrow is a major site of long-term antibody production after acute viral infection , 1995, Journal of virology.
[52] R. Welsh,et al. T cell-independent antibody-mediated clearance of polyoma virus in T cell-deficient mice , 1996, The Journal of experimental medicine.
[53] R. Steinman,et al. Dendritic cells are critical accessory cells for thymus-dependent antibody responses in mouse and in man. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[54] J. Groopman,et al. Characterization of serum neutralization response to the human immunodeficiency virus (HIV). , 1987, AIDS research and human retroviruses.
[55] Q. Sattentau,et al. Altered CD4 interactions of HIV type 1 LAI variants selected for the capacity to induce membrane fusion in the presence of a monoclonal antibody to domain 2 of CD4. , 1996, AIDS research and human retroviruses.
[56] Anthony S. Fauci,et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.
[57] I. Williams,et al. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. , 1996, The Journal of infectious diseases.
[58] A. Lanzavecchia. Antigen Uptake and Accumulation in Antigen‐Specific B Cells , 1987, Immunological reviews.
[59] R. Zinkernagel,et al. The influence of antigen organization on B cell responsiveness. , 1993, Science.
[60] D. Klinman,et al. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. , 1992, The Journal of clinical investigation.
[61] B. Walker,et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. , 1996, AIDS research and human retroviruses.
[62] R M Zinkernagel,et al. How many specific B cells are needed to protect against a virus? , 1994, Journal of immunology.
[63] M. Jackson,et al. Peptide binding and presentation by mouse CD1. , 1995, Science.
[64] J. Hansen,et al. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. , 1993, The Journal of general virology.
[65] J. Sodroski,et al. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. , 1985, Science.
[66] R. Gallo,et al. Stimulatory and inhibitory influences of human immunodeficiency virus on normal B lymphocytes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[67] D. Berns,et al. Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24 , 1989, Journal of clinical microbiology.
[68] Alan S. Perelson,et al. Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue , 1996, Science.
[69] C. Nielsen,et al. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man. , 1995, AIDS (London).
[70] Antonio Lanzavecchia,et al. Antigen-specific interaction between T and B cells , 1985, Nature.
[71] J. Albert,et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.
[72] Q. Sattentau,et al. The CD4 antigen: Physiological ligand and HIV receptor , 1988, Cell.
[73] L. Wen,et al. Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in alpha beta(+) T cells. , 1994, Nature.
[74] Anthony S. Fauci,et al. Toward an Understanding of the Correlates of Protective Immunity to HIV Infection , 1996, Science.
[75] J. Albert,et al. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. , 1991, Virology.
[76] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[77] M. Gonda,et al. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. , 1985, Science.
[78] M. Georges-Courbot,et al. Human T-lymphotropic virus type I excretion and specific antibody response in paired saliva and cervicovaginal secretions. , 1996, AIDS research and human retroviruses.
[79] A. Venet,et al. Serum HIV antigen and anti-P24-antibodies in 200 HIV seropositive patients: correlation with CD4 and CD8 lymphocyte subsets. , 1988, Clinical and experimental immunology.
[80] R. Moss,et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. , 1994, The Journal of infectious diseases.
[81] D. Ho,et al. Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals , 1993, Journal of virology.
[82] D. Cooper,et al. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. , 1996, The Journal of infectious diseases.
[83] D. Klinman,et al. Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein. , 1994, Journal of acquired immune deficiency syndromes.
[84] C. Barbas,et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.
[85] H. Gelderblom. Assembly and morphology of HIV: potential effect of structure on viral function. , 1991, AIDS.
[86] S. Strathdee,et al. Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS. , 1995, The Journal of infectious diseases.